Merck sheds allergy unit, but hangs on to potential EpiPen competitor

Feb. 20, 2020

Merck KGaA has agreed to sell its allergy unit, Allergopharma, to Dermapharm SE. The companies did not disclose the financial details of the deal, but Allergopharma brought in over $95 million in sales in 2018. 

Merck said it will hang onto Allergopharma’s ongoing development of an adrenaline autoinjector for anaphylactic shock, which could eventually compete with Mylan’s EpiPen.

The deal is expected to close in the second quarter.

Read the Reuters report.